Besides, Zboralski et al. illustrated a key role of CXCL12-CXCR4 axis in conferring resistance to checkpoint inhibitors and blockage of CXCL12 enhanced the efficacy of anti-PD-L1 immunotherapy in a murine model of CRC [39]. The gene discussed is CXCR4; the disease is colorectal carcinoma.